Accuracy Evaluation of CONTOUR®PLUS Compared With Four Blood Glucose Monitoring Systems

Abstract

IntroductionThe aim of this study was to compare the accuracy of 5 blood glucose monitoring systems (BGMSs; CONTOUR®PLUS [CP], Accu-Chek® Active [ACA], Accu-Chek® Performa [ACP], FreeStyle Freedom™ [FF], OneTouch® SelectSimple™ [OTSS]).MethodsStudy staff tested fingerstick samples from 106 subjects aged ≥18 years using the 5 BGMSs. Some samples were modified to achieve blood glucose concentrations throughout the measuring range. The primary endpoint was comparison of the mean absolute relative difference (MARD) from the reference value (Yellow Springs Instruments [YSI]) across the overall tested glucose range. Other endpoints were MARD in the low (≤80 mg/dL [≤4.4 mmol/L]), middle (81–180 mg/dL [4.5–10.0 mmol/L]), and high (>180 mg/dL [>10.0 mmol/L]) glucose ranges, and MARD for unmodified samples in the overall glucose range.ResultsCONTOUR®PLUS had a statistically significantly lower MARD than all BGMSs across the overall tested range (27–460 mg/dL [1.5–25.5 mmol/L]) and in the high glucose range. In the low glucose range, CP had a lower MARD than all BGMSs, which was statistically significant except for ACP. For unmodified samples across the overall tested range, CP had a lower MARD than all BGMSs and was statistically significantly lower except for ACA.ConclusionsCONTOUR®PLUS had the lowest mean difference from the reference values (by MARD) when compared with other BGMSs across multiple glucose ranges with modified and unmodified samples.FundingBayer HealthCare LLC, Diabetes Care.Trial registration number: ClinicalTrials.gov Identifier NCT01714232.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-015-0121-3) contains supplementary material, which is available to authorized users.

The prevalence of metabolic syndrome and its association with body fat distribution in middle-aged individuals from Indonesia and the Netherlands: a cross-sectional analysis of two population-based studies

“…Third, a possible overestimation of hyperglycemia and diabetes in the Indonesian population, as the glucose measures were estimated with a capillary blood test (Accu-Chek Performa, Roche Diagnostics GmbH, Mannheim, Germany) instead of a plasma sample, for logistic reasons [40]. Nevertheless, three studies have shown that the absolute relative difference in glucose concentrations between capillary blood testing and plasma was low (4.5%), resulting in no effect on diabetes diagnosis [41][42][43].…”

Effect of Electrolyte Ions on the Stability of Flavin Adenine Dinucleotide‐Dependent Glucose Dehydrogenase

“…Glucose dehydrogenase (GDH) with flavin adenine dinucleotide (FAD) as a cofactor (FAD‐GDH) has received considerable attention as an electrocatalyst for glucose anodes owing to its excellent substrate selectivity toward glucose, as well as its lack of O 2 reactivity . Although FAD‐GDH has already been used in single‐use blood glucose sensor strips, the long‐term usage of FAD‐GDH‐based electrodes operating at body temperature is limited by the inactivation of enzymes on electrodes because FAD‐GDH has a lower thermal stability than GOx . To extend the lifetime of the enzyme, promising straightforward strategies include the screening of more thermostable FAD‐GDHs from other sources or developing protein‐engineered FAD‐GDHs .…”

Use of new technologies for the management of glycemia in patients with various carbohydrate metabolism disorders during pregnancy

“…Чтобы избежать пороков развития плода и прогрессирования сосудистых осложнений, паци-енткам, особенно с длительностью заболевания более 10 лет, необходимо ежедневно контролировать уровень ГК в домашних условиях, используя портативные глюкометры высокой точности [9,12,22]. Рекомендуемые стандарты самоконтроля уровня ГК до беременности представлены в таблице 3.…”

“…Результаты исследования данного прибора были доложены N. Dunne c соавт. на 73-й научной кон-ференции Амери канской диабетической ассоциации (ADA), была доказана точность прибора «Контур Плюс» при тестировании любой концентрации сахара крови (по всему диапазону измерений) [22]. Данная опция является важной для женщин с незапланированной беременностью и уже диагностированным диабетом до ее наступления.…”